Name: Arcus Biosciences Inc (RCUS) News, Articles, Events & Latest Updates
Creator: Stocktwits

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is surging following a blowout earnings report that shattered expectations for revenue growth, particularly in the U.S. commercial sector. The community is actively debating the company's long-term sustainability versus its high valuation, with bulls celebrating the massive earnings beat while bears remain skeptical of the stock's future performance.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid heavy volatility as investors react to a strategic debt-for-equity exchange, with the community sharply divided over whether the dilution signals a long-term turnaround plan or continued value erosion for retail holders. Traders are actively debating the impact of the 35-day VWAP window on future dilution, while some see the cleaner balance sheet as preparation for a potential acquisition.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors weigh strong advertising momentum and subscription growth against persistent concerns regarding user growth in North America and the long-term impact of its hardware initiatives. Community discussions are highly polarized, with many traders anticipating a volatile move following earnings while speculating on potential acquisition interest or a turnaround driven by the company's AI-integrated advertising tools.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors grow increasingly expectant of a catalyst related to the Phase 3 REGAL trial, with community sentiment heavily focused on the potential unblinding of the 80th event. Discussions are dominated by bullish speculation regarding clinical outcomes, institutional ownership shifts, and the long-term strategic value of the company's immunotherapy pipeline in the context of broader oncology sector consolidation.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to heightened volatility and market skepticism surrounding ongoing geopolitical tensions in the Middle East and reports of potential supply disruptions. Community discussion is dominated by concerns over SPR drawdowns, conflicting news regarding peace negotiations, and accusations that political figures are manipulating oil prices for financial or strategic gain.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense & National Security, Space Solutions, and Starlab Space Stations. The Defense & National Security segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Space Solutions segment consists of space infrastructure, advanced space technology, science systems and mission services. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyager Technologies (VOYG) is surging following a strong quarterly earnings report that featured a record backlog and an increase to full-year revenue guidance, sparking significant buying momentum. Investors are actively discussing the company's scaling space infrastructure platform and its competitive positioning in government-backed defense and lunar exploration contracts.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is seeing intense community engagement as investors closely monitor the highly anticipated Phase 3 IZAR-1 trial results. While the community is frustrated by recent price stagnation and institutional insider selling, sentiment remains heavily anchored in the potential for best-in-class data to serve as a catalyst for a significant re-rating or acquisition.

Sterling Infrastructure, Inc. engages in the provision of construction solutions. It operates through the following segments: Transportation Solutions, E-Infrastructure Solutions, and Building Solutions. The Transportation Solutions segment provides infrastructure and rehabilitation services for highways, roads, bridges, airports, ports, light rail systems, water and wastewater facilities, and storm drainage systems. The E-Infrastructure Solutions segment develops advanced, large-scale site development systems and services for data centers, e-commerce distribution centers, warehousing facilities, transportation projects, energy infrastructure, and other specialized developments. The Building Solutions segment provides residential and commercial concrete foundation services for single-family and multi-family homes, as well as parking structures, elevated slabs, and other concrete construction projects. The company was founded in 1955 and is headquartered in The Woodlands, TX.

Sterling Infrastructure Inc

Sterling Construction Company, Inc.

Sterling Infrastructure is experiencing heightened volatility as investors debate whether the stock's valuation can sustain its momentum ahead of the upcoming earnings release. While the community remains optimistic about its data center and AI infrastructure backlog, the share price has faced significant pressure during a broader market rotation, leading traders to closely monitor support levels for potential buying opportunities.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is seeing high volatility and heavy trading volume following a leadership transition to interim CEO Daniel Lewis and a capital raise that sparked significant community debate. While the stock faced sharp selling pressure, the community remains intensely focused on the company's AI-driven growth trajectory, potential for a short squeeze, and the impact of upcoming earnings on its path to profitability.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Carnival Corp is trending as investors weigh strong demand metrics and record booking trends against the ongoing impact of elevated fuel costs and Middle East geopolitical tensions ahead of the latest earnings report. The community remains divided between long-term bulls highlighting robust fundamentals and valuation gaps relative to peers, and bearish traders pointing to persistent price volatility and the stock's sensitivity to energy market shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Companys Board of...

SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus

Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study 

Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG...

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company...

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on...

Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?

HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casdatifan in first-line ccRCC.read more...

An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run

Key PointsThe president of Arcus Biosciences sold 68,569 shares for $2.0 million during the July 9 and July 10 trading sessions...

New Research Published in Nature Links Clinical Activity with HIF2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a publication in Nature describing new research from the...

$RCUS Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.02 up 10.53% YoY
• Reported revenue of $17M down -39.29% YoY
• Arcus Biosciences believes its $876M in cash, cash equivalents, and marketable securities as of March 31, 2026, will fund planned operations until at least the second half of 2028.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Arcus Biosciences Inc

Why Did Arcus Biosciences Stock Slump 10% Today?

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info